PATENT CLAIM ANALYSIS

Application Number: 16248507
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["424", "172100"]

Abstract:
The instant disclosure provides antibodies that specifically bind to ApoC3 (e.g., human ApoC3) and antagonize ApoC3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Claim (Index 3):
The isolated antibody of  claim 1 , wherein CDRL1 comprises the amino acid sequence of KTSQGLVHSDGKTYFY (SEQ ID NO: 6) or KTSQGLVHSGGKTYFY (SEQ ID NO: 40).

Metadata:
- Claim Count in Document: 23.0
- Percentile: 99.0
- Lexical Diversity: 1.36585
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15606148', '15254315', '15166305', '16165833', '15524651']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7685655682075077
- 35 USC 102 Novelty (BERT): 0.5556569535994532
- Combined Prediction Score: 0.7472747067467023
- Mean Citation Score: 428.60382800000014
- Max Citation Score: 446.3738
- Similarity Product: 358.9954909585476

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test